Transitioned to commercialization in Q3 2025 with strategic distribution deals and in-house production. Financials show improved operating loss and EPS, with product launches for Follicopeptide set for December 2025 and further expansion in 2026.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.